Regencell Bioscience Holdings (RGC) Total Current Liabilities (2020 - 2025)
Regencell Bioscience Holdings' (RGC) quarterly Total Current Liabilities came in at $1.7 million in Q4 2025, up 151.0% on a QoQ basis from $663673.0 in Q2 2025.
Regencell Bioscience Holdings (RGC) Total Current Liabilities (2020 - 2025) Analysis & Trends
Regencell Bioscience Holdings (RGC) has 6 years of Total Current Liabilities data on file, last reported at $1.7 million in Q4 2025.
- Quarterly Total Current Liabilities changed N/A year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (changed N/A YoY) and the FY2025 annual result came in at $663673.0, up 242.85% from the prior year.
- Total Current Liabilities grew to $1.7 million in Q4 2025, from $663673.0 in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $4.3 million in Q2 2021 to a low of $193578.0 in Q2 2024.
- A 5-year average of $1.3 million and a median of $635293.5 in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 86.68% — and 2025, when it surged 242.85%.
- Tracing RGC's Total Current Liabilities over 5 years: stood at $4.3 million in 2021, then sank by 86.68% to $577764.0 in 2022, then advanced by 5.05% to $606914.0 in 2023, then slumped by 68.1% to $193578.0 in 2024, then jumped by 760.54% to $1.7 million in 2025.
- The last three Total Current Liabilities figures came in at $1.7 million (Q4 2025), $663673.0 (Q2 2025), and $193578.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.79 Bn |
| 10 | Regencell Bioscience Holdings | 2.67 Bn | 2.67 Bn | - | 1.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.67 Mn |
| Jun 30, 2025 | 663,673.00 |
| Jun 30, 2024 | 193,578.00 |
| Jun 30, 2023 | 606,914.00 |
| Jun 30, 2022 | 577,764.00 |
| Jun 30, 2021 | 4.34 Mn |
| Jun 30, 2020 | 3.16 Mn |